“The PSA clock” by Dr. Michael Glodé

Dr. Michael Glodé is a medical oncologist who practices in Colorado, and who has extensive experience in the management of prostate cancer. He also blogs on a regular basis at prost8blog. Your sitemaster tries to remember to check in on that blog site from time to time because it has long been very clear that Dr. Glodé takes the needs of his patients very seriously. … READ MORE …

PSA testing in the “real world” … from 2010 to 2015

A newly published article in the journal Cancer suggests that, in fact, the USPSTF guidance on use of the PSA test for risk of prostate cancer has had little impact in the “real world” between 2010 and 2015 (at least at one large tertiary care institution in Texas). … READ MORE …

How good is your relationship with your son or sons?

And in today’s exciting news comes something that it is too late for most prostate cancer patients to do anything about personally (and which they can complain about if they did and they still got prostate cancer … although we’re not sure to whom)! … READ MORE …

More on docetaxel given every 2 weeks

A few days ago we reported on a paper by a Finnish research team who had compared treatment of men with mCRPC with docetaxel given every 2 weeks as opposed to the standard therapy of every 3 weeks. … READ MORE …

Docetaxel every 2 weeks (at a lower dose) or every 3 weeks (at the standard dose)

A study by a team of Finnish investigators has suggested that treating patients with metastatic, castration-resistant prostate cancer (mCRPC) with docetaxel chemotherapy every 2 weeks may have better outcomes and fewer side effects than the use of the currently recommended regimen, in which patients are dosed once every 3 weeks. … READ MORE …

Prostate cancer news reports: Saturday, November 21, 2009

In today’s prostate cancer news reports there are brief comments on a number of interesting (if technically dense) articles dealing with such topics as:

  • The need for regularity of post-treatment PSA testing
  • Surgical outcomes of men with Gleason 8-10 disease over 20 years of experience
  • Loss of penile length after radical prostatectomy
  • Does bladder cancer invasion meet the standard for pathologic stage T4? … READ MORE …

AUA report and update no. 12: Friday, May 1, 2009

And still the stream of information continues, with  reports about frequency of PSA testing, nerve-sparing in men with Gleason 6 disease, and HIFU as a form of salvage therapy after first-line radiation: … READ MORE …